Remedium Life

Who are in the management team of Remedium Life?

As of March 2023, the management team of Remedium Life includes Maneesha Naresh (Independent Director), Haonsh Santok (Director, Rs. 12.0 lacs), Vilas Ramkrishna Lokhande (Whole-time Director, Rs. 30.0 lacs), Trupti Bolke (Independent Director), and Dhwani Desai (Company Secretary & Compliance Officer). They oversee the company's operations and governance.

As of March 2023, the management team of Remedium Life includes the following members:<BR><BR>1. Maneesha Naresh - Independent Director<BR>2. Haonsh Santok - Director, with a remuneration of Rs. 12.0 lacs<BR>3. Vilas Ramkrishna Lokhande - Whole-time Director, with a remuneration of Rs. 30.0 lacs<BR>4. Trupti Bolke - Independent Director<BR>5. Dhwani Desai - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the company's operations and governance.

What is the bonus history of the Remedium Life?

Remedium Life's recent bonus history includes a 3:1 bonus announced for July 5, 2024, and a previous 9:5 bonus issued on July 28, 2023. This reflects the company's commitment to rewarding shareholders with bonus shares.

Remedium Life has a notable bonus history. The most recent bonus issue was announced as a 3:1 bonus, with an ex-date of July 5, 2024, and a record date of July 6, 2024. Prior to that, on July 28, 2023, the company issued a bonus in the ratio of 9:5, with the record date set for July 29, 2023. This indicates a proactive approach to rewarding shareholders through bonus shares.

Has Remedium Life declared dividend?

No Dividend History Available

Is Remedium Life overvalued or undervalued?

As of February 17, 2025, Remedium Life's valuation has shifted from fair to risky, indicating overvaluation with a PE ratio of 56.31 and a year-to-date return of -63.63%, significantly underperforming its peers and the market.

As of 17 February 2025, the valuation grade for Remedium Life has moved from fair to risky, indicating a significant deterioration in its perceived value. The company appears to be overvalued, particularly when considering its headline ratios, which include a PE ratio of 56.31, a Price to Book Value of 2.73, and an alarming EV to EBIT of -1114.97. These metrics suggest that investors are paying a premium for earnings that are not being generated, raising concerns about the sustainability of its current valuation.<BR><BR>In comparison to its peers, Remedium Life's valuation stands out unfavorably. For instance, MMTC Ltd. has a PE ratio of 119.39, while PTC India Ltd. boasts a very attractive PE of 9.02, highlighting the disparity in valuation within the industry. Additionally, the company's recent stock performance has been dismal, with a year-to-date return of -63.63%, significantly underperforming the Sensex's 5.56% return during the same period. This further reinforces the notion that Remedium Life is currently overvalued in the market.

What is the technical trend for Remedium Life?

As of June 3, 2025, Remedium Life's technical trend is bearish with moderate strength, supported by bearish Bollinger Bands and moving averages, despite mixed signals from MACD and KST indicators.

As of 3 June 2025, the technical trend for Remedium Life has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. The weekly MACD is mildly bullish, but the monthly MACD is bearish, indicating mixed signals across time frames. The Bollinger Bands are bearish on both weekly and monthly charts, reinforcing the bearish outlook. Daily moving averages also confirm a bearish trend. The KST shows a mildly bullish weekly signal but is bearish monthly, while Dow Theory presents a mildly bearish weekly view and a mildly bullish monthly perspective. Overall, the combination of these indicators suggests a prevailing bearish sentiment in the market for Remedium Life.

Who are the peers of the Remedium Life?

Remedium Life's peers include Franklin Industries, Cravatex, Goyal Aluminiums, Genpharmasec, Safa Systems, Chandrima Mercan, Ganesha Ecoverse, and Le Lavoir. Chandrima Mercan leads in returns and growth, while Remedium Life has the lowest 1-year return at -89.09%.

Peers: The peers of Remedium Life are Franklin Indust., Cravatex, Goyal Aluminiums, Genpharmasec, Safa Systems, Chandrima Mercan, Ganesha Ecoverse, and Le Lavoir.<BR><BR>Quality Snapshot: Excellent management risk is observed at Franklin Indust., while Average management risk is found at Cravatex, Goyal Aluminiums, and Le Lavoir, and the rest have Below Average management risk. Growth is Excellent at Chandrima Mercan, while Average growth is noted at Franklin Indust. and the rest have Below Average growth. Capital Structure is Excellent at Chandrima Mercan, Good at Franklin Indust., Goyal Aluminiums, and Le Lavoir, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Chandrima Mercan at 72.81%, while the lowest is Remedium Life at -89.09%. Remedium Life's 1-year return is significantly lower than all peers. Additionally, Goyal Aluminiums, Genpharmasec, Ganesha Ecoverse, and Le Lavoir have negative six-month returns.

What does Remedium Life do?

Remedium Lifecare Ltd, a Micro Cap company established in 1988, operates in the Trading & Distributors industry, reporting net sales of 816 Cr and a net loss of 26 Cr for the quarter ending March 2025. The company, formerly known as Roxy Exports Limited, has a market cap of INR 107 Cr and key metrics including a P/E of 51.00 and a debt-equity ratio of 25.97.

Overview: <BR>Remedium Lifecare Ltd operates in the Trading & Distributors industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in 1988 and underwent a name change from "Roxy Exports Limited" to "Remedium Lifecare Limited" on November 6, 2020, to align with its new business activities. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 816 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -26 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 107 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 51.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 25.97 <BR>Return on Equity: 4.85% <BR>Price to Book: 2.43 <BR><BR>Contact Details: <BR>Address: Office No 601 Hyder Park, Saki Vihar Road Andheri East Mumbai Maharashtra : 400072 <BR>Email: roxycyclesin@gmail.com <BR>Website: http://www.remlife.com

Who are the top shareholders of the Remedium Life?

The top shareholders of Remedium Life are primarily individual investors, holding 87.29% of the shares, with Siddharth Chimanlal Shah being the largest promoter at 1.11%. There are no institutional holdings or pledged promoter shares.

The top shareholders of Remedium Life primarily consist of individual investors, who hold a significant 87.29% of the company's shares. Among the promoters, Siddharth Chimanlal Shah is the one with the highest holding at 1.11%. There are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings. Overall, the majority of the shares are held by non-institutional investors.

How big is Remedium Life?

As of 24th July, Remedium Lifecare Ltd has a market capitalization of 106.00 Cr and reported Net Sales of 264.32 Cr with a Net Profit loss of 2.05 Cr for the quarter ending March 2025. As of March 2024, Shareholder's Funds were 42.96 Cr and Total Assets were 1,947.90 Cr.

As of 24th July, Remedium Lifecare Ltd has a market capitalization of 106.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest quarter ending March 2025, Remedium Lifecare reported Net Sales of 264.32 Cr. However, the company experienced a loss of 2.05 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, where Shareholder's Funds amounted to 42.96 Cr and Total Assets were reported at 1,947.90 Cr.

Are Remedium Life latest results good or bad?

Remedium Lifecare's latest results are mixed but lean negative, with a net profit increase driven by non-operating income, while net sales declined and financial leverage poses significant risks. Overall, concerns about revenue volatility and sustainability overshadow the positive indicators.

The latest results for Remedium Lifecare present a mixed picture, but overall, they lean towards the negative side. In Q2 FY26, the company reported a net profit of ₹8.62 crores, which is an impressive increase of 85.38% quarter-on-quarter. However, this surge in profitability is somewhat misleading, as it heavily relies on non-operating income, which accounted for about 30.61% of the operating profit. <BR><BR>On the other hand, net sales declined by 2.04% from the previous quarter, continuing a troubling trend of revenue volatility. The company's operating profit margin improved to 6.64%, but this follows a history of erratic performance, including a negative operating margin in the previous quarter.<BR><BR>Additionally, the financial health of Remedium Lifecare raises concerns. The company operates with extreme financial leverage, indicated by a net debt-to-equity ratio of 25.97, which poses significant risks. The absence of institutional backing and minimal promoter holding (just 1.13%) further complicates its outlook.<BR><BR>In summary, while there are some positive indicators, such as improved margins and sequential profit recovery, the overall financial stability and sustainability of earnings remain questionable. Therefore, the results can be viewed as more negative than positive, especially considering the company's ongoing challenges and the reliance on non-core income for profitability.

How has been the historical performance of Remedium Life?

For the year ending March 2025, Remedium Life reported an operating income of 405.25 crore and a net profit after tax of 2.13 crore, with an EPS of 0.04. The company faced an operating loss of 1.09 crore before other income and had total liabilities of 1,720.31 crore.

Answer:<BR>The historical performance of Remedium Life for the year ending March 2025 shows a total operating income of 405.25 crore, with a total expenditure of 406.34 crore, resulting in an operating profit (PBDIT) of -1.09 crore. After accounting for other income of 10.80 crore, the operating profit stands at 9.71 crore. The profit before tax is reported at 4.38 crore, leading to a profit after tax of 2.13 crore. The earnings per share (EPS) is 0.04, with a diluted EPS of 0.03. The operating profit margin is -0.27%, while the profit after tax margin is 0.53%. <BR><BR>Breakdown:<BR>Remedium Life's financial results for March 2025 indicate a total operating income of 405.25 crore, which is offset by total expenditures of 406.34 crore, leading to an operating loss of 1.09 crore before considering other income. The company reported other income of 10.80 crore, resulting in an operating profit of 9.71 crore. After accounting for interest expenses of 5.29 crore, the profit before tax is 4.38 crore, with a net profit after tax of 2.13 crore. The company has total liabilities of 1,720.31 crore, with total assets matching this figure, indicating a balanced sheet. Cash flow from operating activities shows a significant outflow of 1,134 crore, while financing activities contributed a net inflow of 1,136 crore, resulting in a slight net cash inflow of 1 crore by the end of the period.

When is the next results date for Remedium Lifecare Ltd?

The next results date for Remedium Lifecare Ltd is March 9, 2026.

The next results date for Remedium Lifecare Ltd is scheduled for March 9, 2026.

Should I buy, sell or hold Remedium Lifecare Ltd?

Why is Remedium Lifecare Ltd falling/rising?

As of 22-Apr, Remedium Lifecare Ltd's stock price is at 0.50, reflecting a 4.17% increase. This rise is driven by strong investor interest and a 42.86% gain over the last 10 days, despite underlying financial weaknesses and a lack of recent results.

As of 22-Apr, Remedium Lifecare Ltd's stock price is rising, currently at 0.50, reflecting a change of 0.02 or 4.17% increase. This upward movement can be attributed to several factors. Notably, the stock has outperformed its sector by 2.93% today and has experienced a consecutive gain over the last 10 days, resulting in a substantial return of 42.86% during this period. Additionally, there has been a significant increase in investor participation, with delivery volume rising by 114.97% against the 5-day average, indicating heightened interest in the stock.<BR><BR>Furthermore, institutional investors have increased their stake by 1.7% over the previous quarter, which suggests a growing confidence among these investors in the company's potential, despite its recent struggles. However, it is important to note that the company has not declared results in the last six months and has reported negative financial metrics, including a weak EBIT to Interest ratio and a significant decline in net sales. While these factors indicate underlying weaknesses, the recent short-term performance and increased trading activity have contributed to the stock's rise.

Which are the latest news on Remedium Life?